Tobam grew its holdings in shares of DexCom, Inc. (NASDAQ:DXCM – Free Report) by 9,010.6% in the course of the third quarter, HoldingsChannel reviews. The institutional investor owned 93,748 shares of the medical system firm’s inventory after shopping for a further 92,719 shares in the course of the interval. Tobam’s holdings in DexCom have been value $6,285,000 on the finish of the latest quarter.
Plenty of different hedge funds have additionally just lately modified their holdings of DXCM. Connectus Wealth LLC purchased a brand new place in DexCom within the fourth quarter value roughly $207,000. Point72 Hong Kong Ltd purchased a brand new stake in DexCom in the course of the 4th quarter valued at $12,341,000. MayTech International Investments LLC boosted its place in DexCom by 0.7% in the course of the 4th quarter. MayTech International Investments LLC now owns 162,852 shares of the medical system firm’s inventory valued at $20,208,000 after buying a further 1,151 shares within the final quarter. C M Bidwell & Associates Ltd. boosted its place in DexCom by 64.0% in the course of the 4th quarter. C M Bidwell & Associates Ltd. now owns 2,959 shares of the medical system firm’s inventory valued at $367,000 after buying a further 1,155 shares within the final quarter. Lastly, Brevan Howard Capital Administration LP boosted its place in DexCom by 326.4% in the course of the 4th quarter. Brevan Howard Capital Administration LP now owns 12,565 shares of the medical system firm’s inventory valued at $1,559,000 after buying a further 9,618 shares within the final quarter. Institutional traders personal 97.75% of the corporate’s inventory.
Insider Exercise at DexCom
In associated information, EVP Sadie Stern offered 426 shares of the corporate’s inventory in a transaction that occurred on Monday, September ninth. The inventory was offered at a mean worth of $69.15, for a complete worth of $29,457.90. Following the transaction, the chief vice chairman now straight owns 75,451 shares within the firm, valued at roughly $5,217,436.65. This represents a 0.00 % lower of their possession of the inventory. The transaction was disclosed in a authorized submitting with the SEC, which is accessible via this hyperlink. In different DexCom information, EVP Michael Jon Brown offered 652 shares of the agency’s inventory in a transaction dated Wednesday, July thirty first. The inventory was offered at a mean worth of $69.55, for a complete transaction of $45,346.60. Following the transaction, the chief vice chairman now owns 66,249 shares of the corporate’s inventory, valued at roughly $4,607,617.95. This commerce represents a 0.00 % lower of their possession of the inventory. The sale was disclosed in a doc filed with the SEC, which may be accessed via this hyperlink. Additionally, EVP Sadie Stern offered 426 shares of the inventory in a transaction dated Monday, September ninth. The inventory was offered at a mean worth of $69.15, for a complete transaction of $29,457.90. Following the sale, the chief vice chairman now owns 75,451 shares of the corporate’s inventory, valued at $5,217,436.65. This commerce represents a 0.00 % lower of their place. The disclosure for this sale may be discovered right here. During the last three months, insiders have offered 1,824 shares of firm inventory value $126,390. Insiders personal 0.30% of the corporate’s inventory.
Wall Road Analysts Forecast Progress
A number of analysts have just lately commented on DXCM shares. Stifel Nicolaus elevated their worth goal on DexCom from $90.00 to $100.00 and gave the corporate a “purchase” ranking in a report on Friday, August twenty third. StockNews.com lowered DexCom from a “purchase” ranking to a “maintain” ranking in a report on Wednesday, October 2nd. Piper Sandler reiterated an “chubby” ranking and set a $90.00 worth goal on shares of DexCom in a report on Monday, August twenty sixth. Royal Financial institution of Canada decreased their worth goal on DexCom from $130.00 to $120.00 and set an “outperform” ranking for the corporate in a report on Tuesday. Lastly, Baird R W lowered DexCom from a “strong-buy” ranking to a “maintain” ranking in a report on Friday, July twenty sixth. Seven analysts have rated the inventory with a maintain ranking, eleven have issued a purchase ranking and one has assigned a powerful purchase ranking to the inventory. In accordance with MarketBeat.com, the inventory at present has a mean ranking of “Reasonable Purchase” and a mean goal worth of $110.69.
View Our Newest Evaluation on DXCM
DexCom Worth Efficiency
Shares of DXCM inventory traded down $0.45 throughout buying and selling hours on Thursday, reaching $69.17. The corporate had a buying and selling quantity of 1,586,812 shares, in comparison with its common quantity of three,801,740. The corporate has a debt-to-equity ratio of 1.00, a fast ratio of two.48 and a present ratio of two.82. The inventory has a fifty day transferring common of $70.25 and a 200-day transferring common of $103.61. The corporate has a market capitalization of $27.51 billion, a price-to-earnings ratio of 44.79, a PEG ratio of two.16 and a beta of 1.18. DexCom, Inc. has a 12-month low of $62.34 and a 12-month excessive of $142.00.
DexCom (NASDAQ:DXCM – Get Free Report) final posted its quarterly earnings outcomes on Thursday, July twenty fifth. The medical system firm reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.04. DexCom had a return on fairness of 31.41% and a internet margin of 16.95%. The enterprise had income of $1 billion in the course of the quarter, in comparison with analyst estimates of $1.04 billion. Throughout the identical interval within the prior 12 months, the enterprise earned $0.34 earnings per share. The enterprise’s income was up 15.3% in comparison with the identical quarter final 12 months. On common, equities analysts anticipate that DexCom, Inc. will publish 1.69 earnings per share for the present 12 months.
DexCom Profile
DexCom, Inc, a medical system firm, focuses on the design, improvement, and commercialization of steady glucose monitoring (CGM) programs in the USA and internationally. The corporate supplies its programs to be used by individuals with diabetes, in addition to to be used by healthcare suppliers. Its merchandise embody Dexcom G6 and Dexcom G7, built-in CGM programs for diabetes administration; Dexcom Share, a distant monitoring system; Dexcom Actual-Time API, which permits licensed third-party software program builders to combine real-time CGM information into their digital well being apps and gadgets; and Dexcom ONE, that’s designed to exchange finger stick blood glucose testing for diabetes therapy choices.
See Additionally
Need to see what different hedge funds are holding DXCM? Go to HoldingsChannel.com to get the most recent 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM – Free Report).
Obtain Information & Scores for DexCom Each day – Enter your electronic mail deal with beneath to obtain a concise day by day abstract of the most recent information and analysts’ rankings for DexCom and associated firms with MarketBeat.com’s FREE day by day electronic mail publication.
